Lung Fung Group Holdings Limited (HKG:2290)

Revenue by Segment

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Retail - Drugs	2.46B	2.02B	1.09B
Retail - Drugs Growth	21.76%	84.71%	-
Total	2.46B	2.02B	1.09B
Total Growth	21.76%	84.71%	-

Revenue by Geography

Financials in millions HKD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Hong Kong	2.41B	1.98B	1.04B
Hong Kong Growth	21.98%	89.72%	-
Chinese Mainland	47.62M	42.65M	51.38M
Chinese Mainland Growth	11.67%	-17.00%	-
Total	2.46B	2.02B	1.09B
Total Growth	21.76%	84.71%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jul 10, 2026

Data Sources Report a data error